Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | USP7 | Q93009 | 2/20 | 0.33 |
| ▸ | GCGR | P47871 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.33 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.33 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TDO2 | P48775 | 1/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20028709 | 0.80 | BACE1 (0.38) | MAPTALDH1A1ESR2KDM4EALOX5 | |
| SCHEMBL22897168 | 0.76 | BACE1 (0.36) | MAPTALDH1A1ESR2KDM4EALOX5 | |
| SCHEMBL20033973 | 0.76 | CHRM2 (0.38) | MAPTALDH1A1ESR2ALOX5BACE1 | |
| SCHEMBL1933832 | 0.71 | LMNA (0.38) | LMNARECQL | |
| SCHEMBL7409018 | 0.71 | LMNA (0.52) | LMNARECQLKCNQ2MAPTALDH1A1 | |
| SCHEMBL11780792 | 0.68 | PTGS1 (0.42) | MAPTALDH1A1KDM4EPDCD1CD274 | |
| SCHEMBL9771901 | 0.66 | LMNA (0.75) | LMNAMAPTKDM4ESMN1; SMN2 | |
| SCHEMBL9870675 | 0.66 | RECQL (0.43) | LMNARECQLMAPTALDH1A1KDM4E | |
| SCHEMBL5907405 | 0.66 | LMNA (0.46) | LMNARECQLKCNQ2MAPTALDH1A1 | |
| SCHEMBL31412182 | 0.65 | BACE1 (0.48) | MAPTALDH1A1ESR2KDM4EALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106089-B2 | Reacting pyrrolylalkylcarbinole, furanylalkylcarbinole or thiophenylalkylcarbinole units; cyclodehydration, hydroboration, oxidation, palladium-catalyzed Suzuki-Miyaura cross-coupling; anticarcinogenic agents, antitumor, and antiproliferative agents; autoimmune and neurodegenerative diseases | CENTRE NATIONAL DE LA RECHERCHE (FR) | 2012-01-31 | — | — | US | disclosed |
| US-20080275103-A1 | Anti-Tubulin Acting Arylpyrrol, Arylfuran And Arylthiophene Derivatives, Method For The Preparation Thereof And For The Use Thereof As An Antimitotic | UNIVERSITE DE RENNES (FR) | 2008-11-06 | — | — | US | disclosed |
| EP-1751100-B1 | ANTI-TUBULIN ACTING ARYLPYRROL, ARYLFULRAN AND ARYLTHIOPENE DERIVATIVES, METHOD FOR THE PREPARATION AND USE THEREOF AS AN ANTIMITOTIC | CENTRE NAT RECH SCIENT (FR) | 2008-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275103-A1 | Anti-Tubulin Acting Arylpyrrol, Arylfuran And Arylthiophene Derivatives, Method For The Preparation Thereof And For The Use Thereof As An Antimitotic | TUBB1, TUBB3, TUBB | LMNA 502/4885RECQL 2877/4885KCNQ2 4645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.